ストックスクリーナーアプリを入手
37.60
2.62%
-1.01
アフターアワーズ：
37.50
-0.10
-0.27%
前日終値:
$38.61
開ける：
$38.05
24時間の取引高:
3.09M
Relative Volume:
0.90
時価総額：
$3.70B
収益：
$2.23B
当期純損益:
$-248.39M
株価収益率:
-13.98
EPS:
-2.69
ネットキャッシュフロー:
$-697.55M
1週間 パフォーマンス:
-0.79%
1か月 パフォーマンス:
-38.21%
6か月 パフォーマンス:
-71.80%
1年 パフォーマンス:
-69.79%
1日の値動き範囲:
$36.96
$38.15
1週間の範囲:
$36.89
$39.55
52週間の値動き範囲:
$34.10
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
37.60 | 3.72B | 2.23B | -248.39M | -697.55M | -2.69 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com
July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st
Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey
FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters
Was Jim Cramer Right About These 11 Stocks? - Insider Monkey
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com
Will Moderna's Rally Continue? - Forbes
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive
SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus
Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch
Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha
Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus
Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance
Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus
Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus
Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News
Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus
Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire
Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance
Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com
Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat
Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns - TipRanks
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):